How much revenue does Betta Pharmaceuticals make?

Betta Pharmaceuticals reported 2.89 billion CNY in revenue for fiscal year 2024, up 17.7% from 2.46 billion CNY in fiscal year 2023. In Q2 2025 revenue was 813.86 million CNY.

Where does Betta Pharmaceuticals make most of its revenue?

China: 99% of revenue by region in fiscal year 2025, followed by Foreign (1%).

What companies are similar to Betta Pharmaceuticals?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Junshi BIO (688180.SS), Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SS), Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS), Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS).

Betta Pharmaceuticals Co., Ltd. (300558.SZ) Stock

About Betta Pharmaceuticals Co., Ltd.

Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China and internationally. The company offers Icotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat first-line treatment of locally advanced or non-small-cell lung cancer (NSCLC); Ensartinib hydrochloride, an anaplastic lymphoma ...

At a glance

Betta Pharmaceuticals reported revenue of 2.89 billion CNY for fiscal year 2024, up 17.7% from fiscal year 2023, and net income of 402.57 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 813.86 million CNY, up 6.4% from a year before. China was its largest region in fiscal year 2025, with 99% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.